Cisplatin resistance is associated with reduced interferon-y-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells
1997

Cisplatin Resistance and HER-2 Expression in Ovarian Cancer Cells

publication Evidence: moderate

Author Information

Author(s): C Marth, M Widschwendter, J Karn, N-P J0rgensen, G Windbichler, AG Zeimet, C Trop, G Daxenbichler

Primary Institution: University Hospital, Innsbruck, Austria; The Norwegian Radiumhospital, Oslo, Norway

Hypothesis

Can interferon-y prevent the development of cisplatin resistance in ovarian carcinoma cells?

Conclusion

Interferon-y treatment did not prevent the development of cisplatin resistance in ovarian carcinoma cells, which instead showed increased HER-2 expression.

Supporting Evidence

  • Both cisplatin-resistant cell lines expressed HER-2 at higher levels than the wild-type cells.
  • Interferon-y treatment increased the expression of tumor-associated antigens in all cell lines.
  • Cisplatin resistance was associated with increased HER-2 protein and RNA levels.

Takeaway

The study found that using interferon-y with cisplatin didn't stop cancer cells from becoming resistant to the drug, and these resistant cells had more of a protein called HER-2.

Methodology

The study involved treating ovarian carcinoma cell lines with cisplatin and interferon-y over 8 months to assess resistance and HER-2 expression.

Limitations

The study was conducted in vitro, which may not fully replicate in vivo conditions.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication